Patents by Inventor Ian James Collins

Ian James Collins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazolo-pyridine derivatives as ligands for GABA receptors
    Patent number: 6479506
    Abstract: Substituted or 6,7-ring fused 1,2,3-triazolo[4,5-b]pyridine derivatives are selective ligands for GABAA receptors useful in the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: November 12, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Howard Barff Broughton, Jose Luis Castro Pineiro, Ian James Collins, Leslie Joseph Street
  • Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands
    Patent number: 6352994
    Abstract: Compounds according to Formula (I) or a salt thereof are selective ligands for GABAA receptors useful for treatment of disorders of the central nervous system:
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: March 5, 2002
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Ian James Collins, Stephen Robert Fletcher, Timothy Harrison, Paul David Leeson, Christopher Richard Moyes, Alan John Nadin, Michael Rowley, Timothy Jason Sparey, Martin Richard Teall
  • Triazolo-pyrimidine as ligands for GABA receptors
    Patent number: 6337331
    Abstract: Substituted or 6,7-ring fused 1,2,3-triazolo[1,5-&agr;]-pyrimidine derivatives are selective ligands for GABAA receptors useful in the treatment of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: January 8, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Howard Barff Broughton, Jose Luis Castro Pineiro, Ian James Collins, Karl Richard Gibson, Michael Rowley, Leslie Joseph Street
  • Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands
    Publication number: 20010018438
    Abstract: Compounds according to Formula (I) or a salt thereof are selective ligands for GABAA receptors useful for treatment of disorders of the central nervous system: 1
    Type: Application
    Filed: January 4, 2001
    Publication date: August 30, 2001
    Applicant: MERCK SHARP & DOHME LIMITED
    Inventors: Ian James Collins, Stephen Robert Fletcher, Timothy Harrison, Paul David Leeson, Christopher Richard Moyes, Alan John Nadin, Michael Rowley, Timothy Jason Sparey, Martin Richard Teall
  • Substituted 1H-pyridinyl-2-ones as GABAA-&agr; 2/3 ligands
    Patent number: 6200982
    Abstract: Substituted 1H-Pyridinyl-2-ones are useful as GABAA-Alpha 2/3 ligands.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: March 13, 2001
    Assignee: Merck & Dohme Limited
    Inventors: Ian James Collins, Stephen Robert Fletcher, Timothy Harrison, Paul David Leeson, Christopher Richard Moyes, Alan John Nadin, Michael Rowley, Timothy Jason Sparey, Martin Richard Teall
  • Substituted piperidine derivatives as selective agonists of 5-HT receptors
    Patent number: 6048878
    Abstract: A compound of formula (I), or a salt or prodrug thereof, is described, wherein G is attached at position 3 or 4 of the piperidine ring and represents halogen or C.sub.1-6 alkoxy; R1 represents C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, aryl(C.sub.1-6)alkyl or heteroaryl (C.sub.1-6)alkyl, any of which groups may be optionally substituted; processes for its preparation and its use in therapy, particularly in the treatment of migraine.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: April 11, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Ian James Collins, Angus Murray MacLeod, Christopher Richard Moyes, Michael Rowley, Graham Andrew Showell
  • Pyrmidine derivatives
    Patent number: 5763448
    Abstract: A class of substituted pyrimidine derivatives are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment of disorders of the dopamine system, in particular schizophrenia ##STR1##
    Type: Grant
    Filed: March 18, 1996
    Date of Patent: June 9, 1998
    Assignee: Merck, Sharp & Dohme Limited
    Inventors: William Robert Carling, Ian James Collins, Michael Rowley, Paul David Leeson
  • Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands
    Patent number: 5686480
    Abstract: A class of fused tricyclic heteroaromatic compounds of formula (I), or a salt thereof or a prodrug thereof containing a fused pyrazole ring are ligands for dopamine receptor subtypes within the body and are therefore of use in the treatment and/or prevention of disorders of the dopamine system, such as schizophrenia.
    Type: Grant
    Filed: March 1, 1996
    Date of Patent: November 11, 1997
    Assignee: Merck, Sharp & Dohme, Ltd.
    Inventors: Ian James Collins, Paul David Leeson, Michael Rowley